Fmr LLC Sells 1,129,050 Shares of Progyny, Inc. (NASDAQ:PGNY)

Fmr LLC decreased its holdings in Progyny, Inc. (NASDAQ:PGNY) by 99.8% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 2,767 shares of the company’s stock after selling 1,129,050 shares during the quarter. Fmr LLC’s holdings in Progyny were worth $46,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently bought and sold shares of PGNY. Bank of New York Mellon Corp raised its stake in Progyny by 3.0% in the second quarter. Bank of New York Mellon Corp now owns 756,228 shares of the company’s stock valued at $21,636,000 after purchasing an additional 22,012 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of Progyny by 31.9% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 22,470 shares of the company’s stock valued at $643,000 after buying an additional 5,428 shares in the last quarter. F M Investments LLC bought a new stake in shares of Progyny during the 2nd quarter worth approximately $326,000. Crossmark Global Holdings Inc. boosted its position in shares of Progyny by 12.4% during the 2nd quarter. Crossmark Global Holdings Inc. now owns 18,286 shares of the company’s stock worth $523,000 after acquiring an additional 2,019 shares in the last quarter. Finally, nVerses Capital LLC increased its stake in Progyny by 925.0% in the second quarter. nVerses Capital LLC now owns 4,100 shares of the company’s stock valued at $117,000 after acquiring an additional 3,700 shares during the last quarter. Institutional investors own 94.93% of the company’s stock.

Progyny Stock Up 0.3 %

Shares of NASDAQ PGNY opened at $14.53 on Thursday. The firm has a market cap of $1.24 billion, a P/E ratio of 25.05, a PEG ratio of 1.64 and a beta of 1.35. Progyny, Inc. has a twelve month low of $13.39 and a twelve month high of $42.08. The company has a 50 day moving average of $15.27 and a 200 day moving average of $20.63.

Progyny (NASDAQ:PGNY) last issued its quarterly earnings data on Tuesday, November 12th. The company reported $0.11 earnings per share for the quarter, missing analysts’ consensus estimates of $0.37 by ($0.26). Progyny had a net margin of 5.03% and a return on equity of 11.36%. The company had revenue of $286.63 million for the quarter, compared to the consensus estimate of $296.85 million. During the same quarter last year, the company earned $0.16 EPS. The firm’s revenue for the quarter was up 2.0% on a year-over-year basis. As a group, equities analysts expect that Progyny, Inc. will post 0.59 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have weighed in on PGNY shares. Jefferies Financial Group cut their target price on shares of Progyny from $31.00 to $24.00 and set a “buy” rating on the stock in a research report on Thursday, September 19th. JPMorgan Chase & Co. restated a “neutral” rating and set a $17.00 price objective (down previously from $22.00) on shares of Progyny in a research report on Monday, December 2nd. Barclays dropped their target price on Progyny from $30.00 to $17.00 and set an “overweight” rating for the company in a research report on Thursday, November 14th. JMP Securities cut Progyny from an “outperform” rating to a “market perform” rating in a report on Thursday, September 19th. Finally, Leerink Partners lowered their price objective on Progyny from $25.00 to $21.00 and set a “market perform” rating for the company in a research note on Thursday, September 19th. Nine equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $25.00.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.